Pages that link to "Q42168863"
The following pages link to Comparative pharmacokinetic interaction profiles of pravastatin, simvastatin, and atorvastatin when coadministered with cytochrome P450 inhibitors (Q42168863):
Displaying 50 items.
- Jupiter to earth: a statin helps people with normal LDL-C and high hs-CRP, but what does it mean? (Q24630160) (← links)
- Pharmacokinetic drug interactions of antimicrobial drugs: a systematic review on oxazolidinones, rifamycines, macrolides, fluoroquinolones, and Beta-lactams (Q24631021) (← links)
- Importance of multi-p450 inhibition in drug-drug interactions: evaluation of incidence, inhibition magnitude, and prediction from in vitro data (Q27009128) (← links)
- Pediatric Statin Administration: Navigating a Frontier with Limited Data (Q28068014) (← links)
- Managing dyslipidemia in HIV/AIDS patients: challenges and solutions (Q28084941) (← links)
- Rhabdomyolysis: pathogenesis, diagnosis, and treatment (Q28087634) (← links)
- Adherence to drug label recommendations for avoiding drug interactions causing statin-induced myopathy--a nationwide register study (Q28535157) (← links)
- Quinine-induced renal failure as a result of rhabdomyolysis, haemolytic uraemic syndrome and disseminated intravascular coagulation (Q33371596) (← links)
- Fibrate/Statin initiation in warfarin users and gastrointestinal bleeding risk (Q33617751) (← links)
- Biological products for the treatment of psoriasis: therapeutic targets, pharmacodynamics and disease-drug-drug interaction implications (Q34099814) (← links)
- Pharmacokinetic non-interaction analysis in a fixed-dose formulation in combination of atorvastatin and ezetimibe. (Q34579515) (← links)
- Pharmacokinetic interaction between nelfinavir and pravastatin in HIV-seronegative volunteers: ACTG Study A5108. (Q34599850) (← links)
- General framework for the quantitative prediction of CYP3A4-mediated oral drug interactions based on the AUC increase by coadministration of standard drugs (Q34656231) (← links)
- Atorvastatin-induced acute elevation of hepatic enzymes and the absence of cross-toxicity of pravastatin (Q34759583) (← links)
- Pharmacokinetic comparison of the potential over-the-counter statins simvastatin, lovastatin, fluvastatin and pravastatin (Q34787395) (← links)
- Reduced esophageal cancer incidence in statin users, particularly with cyclo-oxygenase inhibition (Q34898182) (← links)
- Absence of a significant pharmacokinetic interaction between atorvastatin and fenofibrate: a randomized, crossover, study of a fixed-dose formulation in healthy Mexican subjects. (Q35025924) (← links)
- Gender differences, polypharmacy, and potential pharmacological interactions in the elderly. (Q35473198) (← links)
- Co-medication of statins with contraindicated drugs. (Q35561151) (← links)
- Risk assessment of mechanism-based inactivation in drug-drug interactions (Q36174265) (← links)
- A population-based analysis of the risk of drug interaction between clarithromycin and statins for hospitalisation or death (Q36203546) (← links)
- Identification and Mechanistic Investigation of Drug-Drug Interactions Associated With Myopathy: A Translational Approach (Q36332525) (← links)
- Drug interactions during therapy with three major groups of antimicrobial agents (Q36429699) (← links)
- Overcoming 'ageism' bias in the treatment of hypercholesterolaemia : a review of safety issues with statins in the elderly (Q36475343) (← links)
- Role of P-glycoprotein in statin drug interactions (Q36634221) (← links)
- Simvastatin: present and future perspectives (Q36916934) (← links)
- Rational approach to the treatment for heterozygous familial hypercholesterolemia in childhood and adolescence: a review. (Q36965617) (← links)
- A neuromuscular approach to statin-related myotoxicity. (Q37124768) (← links)
- Co-medication of statins and CYP3A4 inhibitors before and after introduction of new reimbursement policy (Q37161532) (← links)
- Simvastatin: two decades in a circle (Q37165690) (← links)
- Pharmacokinetic drug-drug interactions between 1,4-dihydropyridine calcium channel blockers and statins: factors determining interaction strength and relevant clinical risk management (Q37414997) (← links)
- The effect of simvastatin on the proliferation and differentiation of human bone marrow stromal cells (Q37433910) (← links)
- Computing with evidence Part II: An evidential approach to predicting metabolic drug-drug interactions (Q37440022) (← links)
- Clinical importance of the drug interaction between statins and CYP3A4 inhibitors: a retrospective cohort study in The Health Improvement Network (Q37473382) (← links)
- Clarithromycin substantially increases steady-state bosentan exposure in healthy volunteers (Q37492042) (← links)
- Impact of cholesterol on ABC and SLC transporters expression and function and its role in disposition variability to lipid-lowering drugs (Q37521059) (← links)
- Pharmacokinetic Interactions Between Isavuconazole and the Drug Transporter Substrates Atorvastatin, Digoxin, Metformin, and Methotrexate in Healthy Subjects (Q37631841) (← links)
- Does simvastatin cause more myotoxicity compared with other statins? (Q37634190) (← links)
- Hepatic OATP and OCT uptake transporters: their role for drug-drug interactions and pharmacogenetic aspects (Q37680968) (← links)
- Atorvastatin: safety and tolerability (Q37765562) (← links)
- Clinical Importance of OATP1B1 and OATP1B3 in DrugDrug Interactions (Q37836255) (← links)
- Simvastatin interactions with other drugs (Q37993600) (← links)
- The safety and effectiveness of statins as treatment for HIV-dyslipidemia: the evidence so far and the future challenges (Q38024436) (← links)
- Pediatric pharmacogenomics: a systematic assessment of ontogeny and genetic variation to guide the design of statin studies in children (Q38049379) (← links)
- Model-based approaches to predict drug-drug interactions associated with hepatic uptake transporters: preclinical, clinical and beyond. (Q38075057) (← links)
- Drug interactions with statins (Q38155016) (← links)
- Cytochrome P450 and ischemic heart disease: current concepts and future directions (Q38166022) (← links)
- Genetics and personalized medicine--a role in statin therapy? (Q38167710) (← links)
- Consensus guidelines for optimising antifungal drug delivery and monitoring to avoid toxicity and improve outcomes in patients with haematological malignancy, 2014. (Q38284468) (← links)
- Drug-drug interactions that interfere with statin metabolism (Q38522299) (← links)